SK Life Science, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$30.1M
Doctors Paid
11,782
Transactions
96,427
2024 Total
$5.1M
Payment Breakdown by Category
Research$16.8M (55.8%)
Consulting$2.4M (8.0%)
Food & Beverage$2.4M (7.8%)
Travel$773,296 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16.8M | 2,439 | 55.8% |
| Honoraria | $7.6M | 3,199 | 25.3% |
| Consulting Fee | $2.4M | 394 | 8.0% |
| Food and Beverage | $2.4M | 85,470 | 7.8% |
| Travel and Lodging | $773,296 | 2,597 | 2.6% |
| Education | $112,897 | 2,323 | 0.4% |
| Grant | $18,000 | 4 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $525.00 | 1 | 0.0% |
Payments by Type
Research
$16.8M
2,439 transactions
General
$13.3M
93,988 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 1, Randomized, Double-Blinded, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects | $3.9M | 0 | 23 |
| YKP3089C045 | $1.7M | 0 | 33 |
| YKP3089C040 | $1.5M | 0 | 323 |
| 059566 | $1.2M | 0 | 184 |
| YKP509C003 | $1.1M | 0 | 331 |
| YKP3089C025 | $985,152 | 0 | 211 |
| YKP3089C039 | $893,244 | 0 | 83 |
| 59566 | $671,464 | 0 | 126 |
| YKP3089C033 | $609,105 | 0 | 141 |
| YKP509C002 | $570,371 | 0 | 89 |
| YKP509C001 | $566,267 | 0 | 77 |
| SKL27969C001 | $500,855 | 0 | 39 |
| 1-FA7759 | $441,468 | 0 | 145 |
| YKP3089C013 | $420,687 | 0 | 302 |
| SKL69C01 | $382,484 | 0 | 25 |
| An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures | $345,701 | 0 | 74 |
| 1-Q3RAS | $269,724 | 0 | 95 |
| YKP3089C021 | $234,695 | 0 | 17 |
| 045569 | $231,635 | 0 | 56 |
| 45569 | $163,237 | 0 | 26 |
| YKP3089C049 | $72,950 | 0 | 6 |
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension | $71,812 | 0 | 26 |
| Dr. Rosenfeld CNS consulting | $30,135 | 1 | 3 |
| HEOR Consultants | $4,800 | 2 | 3 |
| C025 Ph3 - PGTC (DBL)-CL-325 | $2,000 | 1 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. William Rosenfeld, M.d, M.D | Neurology | Chesterfield, MO | $2.0M | $0 |
| Danielle Becker, Md, MD | Neurology | Columbus, OH | $483,744 | $0 |
| Gregory Connor, M.d, M.D | Neurology | Tulsa, OK | $411,613 | $0 |
| Selim Benbadis, Md, MD | Neurology | Tampa, FL | $342,085 | $0 |
| Mr. Kenneth Laxer, M.d, M.D | Neurology | San Francisco, CA | $281,070 | $0 |
| Dr. Michael Smith, Md, MD | Neurology | Chicago, IL | $278,622 | $0 |
| Pavel Klein, Md, MD | Neurology | Bethesda, MD | $268,344 | $0 |
| Mohamad Koubeissi, Md, MD | Epilepsy | Washington, DC | $257,938 | $0 |
| Idan Sharon, M.d, M.D | Specialist | Brooklyn, NY | $203,967 | $0 |
| Jesus Pina-Garza, Md, MD | Neurology | Nashville, TN | $195,211 | $0 |
| Dr. Robert Wechsler, Md, Phd, Faan, MD, PHD, FAAN | Clinical Neurophysiology | Boise, ID | $171,026 | $0 |
| David Burdette, Md, MD | Epilepsy | Grand Rapids, MI | $154,434 | $0 |
| Lawrence Seiden, M.d, M.D | Neurology | Atlanta, GA | $143,222 | $0 |
| Steve Chung, M.d, M.D | Neurology | Phoenix, AZ | $141,190 | $0 |
| Amit Verma, Md, MD | Neurology | Houston, TX | $131,526 | $0 |
| Dr. Sheetal Malik, M.d, M.D | Neurology | Topeka, KS | $130,152 | $0 |
| Michael Privitera, Md, MD | Epilepsy | Cincinnati, OH | $130,047 | $0 |
| Dean Naritoku, M.d, M.D | Neurology | Mobile, AL | $127,811 | $0 |
| Dr. Tariq Gheith, M.d, M.D | Neurology | East Lansing, MI | $124,102 | $0 |
| Dr. Richard Ramsay, Md, MD | Epilepsy | Mobile, AL | $118,625 | $0 |
| Lance Kim, Do, DO | Vascular Neurology | Ocala, FL | $113,255 | $0 |
| Dr. James Wheless, Md, MD | Neurology with Special Qualifications in Child Neurology | Memphis, TN | $112,653 | $0 |
| John Stern, Md, MD | Clinical Neurophysiology | Los Angeles, CA | $111,612 | $0 |
| Erasmo Passaro, M.d, M.D | Clinical Neurophysiology | St Petersburg, FL | $106,707 | $0 |
| Raman Sankar, M.d, M.D | Neurodevelopmental Disabilities | Los Angeles, CA | $106,065 | $0 |
Ad
Top Products
- XCOPRI $17.6M
- Cenobamate $3.9M
Associated Products (2)
- XCOPRI $17.6M
- Cenobamate $3.9M
Payment Categories
- Food & Beverage $2.4M
- Consulting $2.4M
- Travel & Lodging $773,296
- Research $16.8M
About SK Life Science, Inc.
SK Life Science, Inc. has made $30.1M in payments to 11,782 healthcare providers, recorded across 96,427 transactions in the CMS Open Payments database. In 2024, the company paid $5.1M. The top product by payment volume is XCOPRI ($17.6M).
Payments were distributed across 169 medical specialties. The top specialty by payment amount is Neurology ($9.0M to 3,979 doctors).
Payment categories include: Food & Beverage ($2.4M), Consulting ($2.4M), Research ($16.8M), Travel & Lodging ($773,296).
SK Life Science, Inc. is associated with 2 products in the CMS Open Payments database.